Evidence map›Paper›PMID 42429666›Full record

Trial reportmSystems2026

Sialidase inhibitor modulates gut microbiota and enhances mucosal protection in the treatment of ulcerative colitis.

Yiming Zhao, Lulu Chen, Chunyan Li, Yi Xu, Jing Huang, Shuijiao Chen, Zheng Yu, Xiaowei Liu

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in mSystems, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yiming Zhao *Department of Gastroenterology, Xiangya Hospital Central South University, Changsha, China.
Lulu Chen *Department of Gastroenterology, Xiangya Hospital Central South University, Changsha, China.
Chunyan LiHuman Microbiome and Health Group, Department of Microbiology, Xiangya School of Basic Medical Sciences, Central South University, Changsha, China.
Yi XuDepartment of Gastroenterology, Xiangya Hospital Central South University, Changsha, China.
Jing HuangHuman Microbiome and Health Group, Department of Microbiology, Xiangya School of Basic Medical Sciences, Central South University, Changsha, China.
Shuijiao ChenDepartment of Gastroenterology, Xiangya Hospital Central South University, Changsha, China.ORCID 0000-0002-0111-3600
Zheng YuHuman Microbiome and Health Group, Department of Microbiology, Xiangya School of Basic Medical Sciences, Central South University, Changsha, China.ORCID 0000-0001-7366-3946
Xiaowei LiuDepartment of Gastroenterology, Xiangya Hospital Central South University, Changsha, China.ORCID 0000-0002-1193-4277

Funding

Central South University Innovation-Driven Research Programme 2023CXQD059National Natural Science Foundation of China 32170071National Natural Science Foundation of China 82470564 82270564Natural Science Foundation of Hunan Province 2022JJ30916Natural Science Foundation of Hunan Province 2022JJ40770
6 · The paper itself

Abstract

Ulcerative colitis (UC) is characterized by mucosal barrier erosion, a process exacerbated by bacterial sialidases. We investigated the therapeutic efficacy of the sialidase inhibitor (SI) in UC. In a pilot randomized clinical trial, SI intervention significantly improved clinical symptoms and endoscopic outcomes in mild-to-moderate UC patients. This improvement correlated with an enrichment of butyrate-producing taxa and beneficial metabolic pathways. In a dextran sulfate sodium-induced colitis mouse model, SI attenuated inflammation and restored mucus layer integrity, accompanied by increased expression of

Indexed as

Colitis, UlcerativeEnzyme InhibitorsGastrointestinal MicrobiomeIntestinal MucosaNeuraminidaseAnimalsDextran SulfateDisease Models, AnimalFemaleHumansMaleMiceDextran SulfateEnzyme InhibitorsNeuraminidasegut microbiomeintestinal mucus layermetabolomicsmucus layerulcerative colitis

Identifiers

PMID42429666
PMCPMC13483315

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.